RecruitingNot ApplicableNCT07365553
Omega-3, Autism Spectrum Disorder (ASD)
Omega-3 Fatty Acids and Autism Spectrum Disorder (ASD) - A Double-blind Randomized Controlled Trial of Omega-3 Fatty Acids in Youth With ASD
Sponsor
China Medical University Hospital
Enrollment
50 participants
Start Date
Jul 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Inclusion Criteria4
- diagnosis of DSM5 ASD made by child and adolescent psychiatrist
- age 6-17 years-old at the time of enrolment
- no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,
- Signed informed consent.
Exclusion Criteria4
- comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder
- comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders
- currently using omega-3 supplements or probiotics
- allergy to omega-3.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTOmega-3
Omega-3 PUFAs
DIETARY_SUPPLEMENTPlacebo
Soybean Oil
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07365553
Related Trials
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
NCT073039071 location
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
NCT073044401 location
Differences in N-CAD Concentration and Brain Function Between Children With ASD and TD
NCT074004841 location
Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism
NCT048995441 location
MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD
NCT051942541 location